Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268180 | 0.81 | KDM4E (0.67) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL3587930 | 0.80 | KDM4E (0.69) | KDM4EHSD17B10LMNAAPEX1PTGDR2 | |
| SCHEMBL4292873 | 0.80 | KDM4E (0.65) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL11145191 | 0.80 | KDM4E (0.65) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL15643567 | 0.80 | APEX1 (0.63) | KDM4EHSD17B10LMNAAPEX1PTGDR2 | |
| SCHEMBL15643258 | 0.80 | APEX1 (0.71) | KDM4EHSD17B10LMNAAPEX1PTGDR2 | |
| SCHEMBL7922238 | 0.79 | LMNA (0.66) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL2220542 | 0.79 | LMNA (0.59) | KDM4EHSD17B10LMNAAPEX1ALDH1A1 | |
| SCHEMBL569988 | 0.79 | KDM4E (0.70) | KDM4EHSD17B10LMNAPTGDR2ALDH1A1 | |
| SCHEMBL3970391 | 0.79 | LMNA (0.58) | LMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2601192-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| WO-2012018909-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1883419-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006121588-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121904-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121860-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | KDM4E 2974/4885HSD17B10 1838/4885LMNA 2982/4885 |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | KDM4E 4631/4885HSD17B10 1466/4885LMNA 4724/4885 |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | KDM4E 1619/4885HSD17B10 140/4885LMNA 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.